Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials. Alzforum, 21 May 2016 Vandenberghe R, Rinne JO, Boada M, Katayama S, Scheltens P, Vellas B, Tuchman M, Gass A, Fiebach JB, Hill D, Lobello K, Li D…